HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Clioquinol

HCID 2788
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
130-26-7
Standard SMILES
Oc1c(I)cc(Cl)c2cccnc12
InChIKey
QCDFBFJGMNKBDO-UHFFFAOYSA-N
Molecular formula
C9H5ClINO
Average molar mass
305.5 g/mol
Monoisotopic mass
304.91044

Overview

Iodochlorohydroxyquinoline is a cream-colored to brownish-yellow powder. Practically odorless. Decomposes at 178-179 °C. Used as a topical anti-infective.

Names & identifiers

Preferred name
Clioquinol
IUPAC
5-chloro-7-iodoquinolin-8-ol
English name
Clioquinol
Molecular formula
C9H5ClINO
Molecular weight
305.5

Names & synonyms

clioquinol130-26-75-Chloro-7-iodoquinolin-8-olIodochlorhydroxyquinChloroiodoquinVioform5-Chloro-8-hydroxy-7-iodoquinolineChloroiodoquineCliquinol5-Chloro-7-iodo-8-quinolinolIodochloroxyquinolineIodoenterol
Show more names
IODOCHLOROHYDROXYQUINOLINENystaform5-Chlor-7-jod-8-hydroxy-chinolinIODOCHLOROHYDROXYQUINOLINE (CLIOQUINOL)AmebilBactolhysone
5-Chloro-7-iodo-8-hydroxyquinoline7-Iodo-5-chloroxineIodochloroquineAlchloquinBarquinolChlorojodochinEczecidinEnterozol

Database identifiers

CAS
130-26-7
PubChem CID
2788
DTXSID
DTXSID7022837
ChEMBL
CHEMBL497
ChEBI
CHEBI:74460
UNII
7BHQ856EJ5
EC Number
204-984-4
Nikkaji
J5.432A

Properties

Computed structural propertiesFilling in

XLogP
3.5
Topological polar surface area
33.1 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
2
Rotatable bonds
0
Heavy atoms
13
Formal charge
0
Complexity
192

Experimental & physicochemical properties

Chemical ClassesOther Uses -> Pharmaceuticals
Drugs · 2 items

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

Odor · 2 items

Practically odorless

Slight characteristic odor

Color/Form · 3 items

Brownish-yellow, bulky powder

Yellow brown needles from alcohol, acetic acid.

A voluminous, spongy, yellowish to white brownish powder

Solubility · 4 items

less than 1 mg/mL at 68 °F (NTP, 1992)

One part dissolves in 43 parts of boiling alcohol, 128 parts chloroform, 17 parts of boiling ethyl acetate, 170 parts of cold acetic acid, 13 parts of boiling acetic acid. Almost insol in water, and alcohol, ether.

Practically insol water and in alcohol

0.8 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (41.5%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 147 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 2 items

Chemical: 8-Quinolinol, 5-chloro-7-iodo-

REACH registered substance: Clioquinol (EC: 204-984-4)

Other Safety InformationIMAP assessments - 8-Quinolinol, 5-chloro-7-iodo-: Environment tier I assessment
Fire HazardsFlash point data for this chemical are not available; however, it is probably combustible. (NTP, 1992)
Health Hazards · 1 item

SYMPTOMS: Symptoms of exposure to this compound include changes in central nervous system electrical function and optic nerve damage. Other symptoms include abdominal discomfort, diarrhea, paresthesias in the legs (possibly progressing to paraplegia), loss of visual acuity (sometimes leading to irreversible blindness), characteristic green pigmentation of the tongue, feces and urine, sensory disturbances and subacute myelo-optic neuropathy. Irritation of the skin, eyes, mucous membranes and upper respiratory tract may occur.

Hazards Summary · 1 item

Allergic contact dermatitis reported in patients using this antibiotic topically; [Marks, p. 123-4] An epidemic of subacute myelo-optico-neuropathy occurred in Japan from 1956 until 1970. Approximately 10,000 cases were reported with visual impairment, lower extremity paresthesias and weakness, and other symptoms. Symptoms resolved after the oral medication was discontinued. Neurotoxicity developed in patients who received total doses greater that 750 mg/day for four weeks. [HSDB]

Chemistry & industry

Pharmacology

ATC Code · 6 items

S - Sensory organs

D - Dermatologicals

P - Antiparasitic products, insecticides and repellents

D - Dermatologicals

G - Genito urinary system and sex hormones

QS - Sensory organs

Pharmacodynamics · 1 item

Clioquinol is a broad-spectrum antibacterial with antifungal properties. Application of clioquinol to extensive or eroded areas of the skin may lead to increased protein-bound iodine (PBI) levels within 1 week. In addition, elevated PBI levels may occur when relatively small areas of the skin are treated with clioquinol for more than 1 week.

Mechanism of ActionClioquinol is bacteriostatic, however, the precise mechanism of its action is unknown.
Biological Half-Life11-14 hr
Metabolism/MetabolitesClioquinol has known human metabolites that include Clioquinol O-glucuronide.
FDA Pharmacological Classification · 6 items

7BHQ856EJ5

CLIOQUINOL

Established Pharmacologic Class [EPC] - Standardized Chemical Allergen

Physiologic Effects [PE] - Increased Histamine Release

Physiologic Effects [PE] - Cell-mediated Immunity

Chemical Structure [CS] - Allergens

Absorption, Distribution and Excretion · 3 items

Topical absorption is rapid and extensive, especially when the skin is covered with an occlusive dressing or if the medication is applied to extensive or eroded areas of the skin. Clioquinol is absorbed through the skin in sufficient amounts to affect thyroid function tests.

Clioquinol is absorbed systemically following topical application to the skin. In 2 studies in which clioquinol combined with a corticosteroid was applied topically to the skin as a cream or ointment, it was estimated that about 2-3% of the dose was absorbed systemically. However, in another study in which the drug was applied alone to the skin as a 3% cream and covered with an occlusive wrap for 12 hr, it was estimated that about 40% of the dose was absorbed percutaneously during this period.

Related reactions

12 records
New reaction record
HRID 382880 reaction equation
HRID 382880As reactant
HRID 382881 reaction equation
HRID 382881As reactant
HRID 623403 reaction equation
HRID 623403As reactant
HRID 800732 reaction equation
HRID 800732As reactant
HRID 828411 reaction equation
HRID 828411As reactant
HRID 872226 reaction equation
HRID 872226As reactant
HRID 1069520 reaction equation
HRID 1069520As reactant
HRID 1069521 reaction equation
HRID 1069521As reactant
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Animal Drugs
FDA approved animal drugs -> Active ingredient
DecompositionWhen heated to decomposition it emits very toxic fumes of /hydrogen chloride, hydrogen iodide and nitrogen oxides/.
Melting Point · 2 items

352 to 354 °F (NTP, 1992)

178-179 °C

Physical DescriptionIodochlorohydroxyquinoline is a cream-colored to brownish-yellow powder. Practically odorless. Decomposes at 178-179 °C. Used as a topical anti-infective.
Stability/Shelf LifeClioquinol darkens on exposure to light.
Collision Cross Section138.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
175 · 175-183 °C
Boiling point
350.4 · 350.4±37.0 °C(Predicted)
Density
1.8959 · 1.8959 (estimate)
vapor pressure
0 Pa · 0Pa at 25℃
storage temp.
2 · 2-8°C
solubility
Soluble in DMSO (>25 mg/ml), boiling alcohol ((1:43)), methanol, and chloroform ((1:120)).
pka
8.12 · pKa 8.12(50%aqEtOH t=35.0±0.1 I=0.00 N2atmosphere)(Approximate)
form
Solid
color
Light Beige to Beige
Water Solubility
0.1 g/100 · <0.1 g/100 mL at 20 ºC
Merck
14 · 14,5031
BRN
153637 · 153637
Major Application
forensics and toxicologypharmaceutical (small molecule)
InChI
1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
InChIKey
QCDFBFJGMNKBDO-UHFFFAOYSA-N
SMILES
Oc1c(I)cc(Cl)c2cccnc12
LogP
1.523 at · 1.523 at 24℃
CAS DataBase Reference
130 · 130-26-7(CAS DataBase Reference)
EWG's Food Scores
1 · 1
FDA UNII
7 BHQ856EJ5 · 7BHQ856EJ5
NCI Drug Dictionary
clioquinol
ATC code
8 AH30,D09AA10,G01AC02,P01AA02,P01AA52,S02AA05 · D08AH30,D09AA10,G01AC02,P01AA02,P01AA52,S02AA05
NIST Chemistry Reference
5 · 5-Chloro-7-iodo-8-quinolinol(130-26-7)
EPA Substance Registry System
Clioquinol (130-26-7)
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
301 · H301-H315-H317-H319
Precautionary statements
261 · P261-P264-P280-P301+P310-P302+P352-P305+P351+P338
PPE
2 · Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
Hazard Codes
T
Risk Statements
25 · 25
Safety Statements
36 · 36/37/39-45
RIDADR
2811 · UN 2811 6.1/PG 3
WGK Germany
3 · 3
RTECS
5075000 · VC5075000
TSCA
TSCA listed
HazardClass
6.1 · 6.1(b)
PackingGroup
III
HS Code
2933492250 · 2933492250
Storage Class
6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
3 OralEye · Acute Tox. 3 OralEye Irrit. 2Skin Irrit. 2Skin Sens. 1
Hazardous Substances Data
130 · 130-26-7(Hazardous Substances Data)
Toxicity
50 orally · LD50 orally in cats: 400 mg/kg (Davis)
REACH Registrations
Inactive
FDA Requirements · 2 items

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl clioquinol hydrocortisone and clioquinol nystatin, approved on the basis of safety and effectiveness by FDA under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. /Clioquinol hydrocortisone and clioquinol nystatin/

Reactive GroupAmines, Phosphines, and Pyridines
Reactivity ProfileIODOCHLOROHYDROXYQUINOLINE is incompatible with strong oxidizing agents, strong acids, acid chlorides and acid anhydrides (NTP, 1992). Darkens on exposure to light.
Air and Water ReactionsInsoluble in water.
Hazard Classes and CategoriesAcute Tox. 3 (41.5%)

Safety & protection

Fire FightingFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)
First Aid · 1 item

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Storage ConditionsClioquinol cream should be stored in collapsible tubes or in tight, light-resistant containers. Topical preparations containing clioquinol should be stored at a temperature less than 30 °C; freezing should be avoided.
Nonfire Spill Response · 1 item

SMALL SPILLS AND LEAKAGE: If a spill of this chemical occurs, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with acetone and transfer the dampened material to a suitable container. Use absorbent paper dampened with acetone to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with acetone followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Personal Protective Equipment (PPE) · 1 item

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

Toxicology

Adverse EffectsSkin Sensitizer - An agent that can induce an allergic reaction in the skin.
Human Toxicity Excerpts · 5 items

Beginning in 1956, an epidemic of a new GI neurologic syndrome, subacute myelo-optico-neuropathy, occurred in Japan. When it was publicly announced on August 7, 1970, approximately 10,000 cases had already been reported. Its etiologic agent was identified as iodochlorhydroxyquin. By September 8, 1970, all halogenated hydroxyquinolines were removed from the market in Japan. Since then, the epidemic has not recurred.

Criteria for the diagnosis of subacute myelo-optico-neuropathy. Cardiac Signs: Abdominal symptoms (abdominal pain, diarrhea, etc.) before the onset of neurological symptoms. Acute or subacute onset of bilateral ascending paresthesia and dysesthesia of the lower extremities. Other Major Signs: Impairment of deep sensation and weakness in the lower limbs, with or without pyramidal signs. Less commonly, sensorimotor disturbances in the upper limbs. Occasionally, one or more of the following: a. Bilateral impairment of vision. b. Disturbances of consciousness, convulsions, psychic symptoms, and other cerebral symptoms. c. Greenish discoloration of the tongue and feces. d. Sphincter disturbances. Protracted course with occasional relapses. No significant laboratory findings in blood and cerebrospinal fluid. Rare occurrence in children.

... There have been many similar cases of subacute myelo-optico-neuropathy scattered in various parts of the world affecting adults, with convincing histories relating clioquinol to disturbances of vision, with varying deg of spinal cord involvement. Visual disturbances have ranged from impairment of discrimination of colors to blindness from optic atrophy, with moderate involvement in the form of central scotomas with symmetrically reduced visual acuity. Clinical ophthalmoscopic abnormality appears to be limited to pallor of the disc in eyes with optic atrophy. In a number of cases there has been improvement of vision during several months after administration of clioquinol was discontinued. No treatment has been effective other than stopping administration of clioquinol.

Some of the earliest suspicions of toxicity affecting vision were in relation to children who were being treated for acrodermatitis enteropathica for long periods with large doses when their vision was found to be much impaired, and optic atrophy was diagnosed. Some children had difficulty in walking as well as poor vision. An investigating committee reported in 1974 knowledge of more than a dozen children with optic neuropathy from clioquinol. Less than half had symptoms of peripheral neuropathy.

A neurotoxicity dose response curve for iodochlorhydroxyquin can be constructed as follows: 750 mg/day for 4 wk or less little risk of toxic reactions. 750-1500 mg/day for less than 2 wk 1% have neurologic symptoms. 750-1,500 mg/day for over 2 wk 35% develop symptoms. 1800 mg/day for 5 days one patient developed symptoms. At higher doses onset of toxic reactions may begin within 24 hr after beginning therapy. The clinical symptoms associated with ingestion of halogenated hydroxyquinolines are primarily those of peripheral neuropathy or myelopathy, with occasional cerebral manifestations. Symptoms range from minimal dysesthesia to death and include optic atrophy.

Non-Human Toxicity Excerpts · 1 item

In dogs, clioquinol caused decrease of visual acuity, with vacuolation and loss of axons in the optic tract. There seems to be agreement that peripheral nerves are not primarily affected, but that long tracts in the spinal cord show degeneration, and that the relatively short axons of the optic nerves are especially vulnerable. The seemingly unique distribution has been termed central distal axonopathy. Demyelination follows axon degeneration.

Populations at Special Risk... Use in those younger than 2 years of age is contraindicated.
Antidote and Emergency Treatment · 1 item

Emesis induction is indicated after adult ingestion of 1,500 to 1,800 mg of clioquinol if there is no coma, convulsions, or loss of gag reflex. Otherwise, gastric lavage with tracheal protection, activated charcoal, and cathartics. There are no data on the use of forced diuresis, hemodialysis, peritoneal dialysis, hemoperfusion, or exchange transfusion in the treatment of halogenated 8-hydroxyquinoline poisonings. There are no antidotes.

Regulatory information

FDA Requirements · 2 items

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl clioquinol hydrocortisone and clioquinol nystatin, approved on the basis of safety and effectiveness by FDA under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. /Clioquinol hydrocortisone and clioquinol nystatin/

Safety data

PPE
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
wgk
3
tsca
TSCA listed
rtecs
VC5075000
ridadr
UN 2811 6.1/PG 3
hs_code
2933492250
Toxicity
LD50 orally in cats: 400 mg/kg (Davis)
risk_code
25
Signal word
Danger
Symbol(GHS)
GHS06
hazard_code
T
safety_code
36/37/39-45
hazard_class
6.1(b)
Storage Class
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
packing_group
III
Hazard statements
H301-H315-H317-H319
REACH Registrations
Inactive
Hazard Classifications
Acute Tox. 3 OralEye Irrit. 2Skin Irrit. 2Skin Sens. 1
Precautionary statements
P261-P264-P280-P301+P310-P302+P352-P305+P351+P338
Hazardous Substances Data
130-26-7(Hazardous Substances Data)

Patients with widespread dermatitis were treated with 15-20 g of 3% clioquinol ointment to 40% of the body area twice daily. The serum concentration increased to 0.8-1.2 ug/ml within 4 hr of application. In one patient, 15-20 mg was excreted in the urine daily mainly in the form of conjugated metabolites. This skin treatment resulted in a urinary excretion somewhat less than is obtained after a daily oral dose of 25 mg (one tablet) of clioquinol. Thus, 3-4% of the applied clioquinol was absorbed. 25% was excreted in the urine.

Uses & manufacturing

Uses · 4 items

Used as a medicinal cream, ointment, or powder; [HSDB]

MEDICATION (VET)

MEDICATION

Use (kg; approx.) in Germany (2009): >250

Formulations/Preparations · 4 items

Topical Cream 3%, Iodochlorhydroxyquin Cream, CMC.

Topical Cream, 3% with Hydrocortisone 0.5%, Ala-Quin, Del-Ray; Vioform -Hydrocortisone Mild, Ciba; 3% with Hydrocortisone 1%, Corque, Geneva; Cortin, C & M Pharmacal; Hysone, Mallard; Vioform -Hydrocortisone; Ciba 3% with Hydrocortisone 1% and Pramoxine Hydrochloride 1% 1 + 1-F, Dunhall Lotion, 0.75% with Hydrocortisone 0.25%, UAD Lotion (with parabens and propylene glycol), UAD Laboratories Ointment, 3% with Hydrocortisone 1%, Vioform-Hydrocortisone, Ciba.

Cream and ointment, 3%

Clipquinol is available in the United States and elsewhere as a 3% ointment or cream and a powder.

General Manufacturing Information · 2 items

8-Quinolinol, 5-chloro-7-iodo-: ACTIVE

Sterilizable substitute for iodoform.

Applications · 4 items

Usesalpha adrenergic blocker, mydriatic, antidepressant

UsesUsed as a topical antifungal treatment

UsesClioquinol is used as an anti-infective agent; antiamoebic agent; intravaginal trichomonacide; used to impregnate cotton bandages for antibacterial purposes; in animals as an intestinal anti-infective agent.

General DescriptionCream-colored to brownish-yellow powder. Practically odorless. Decomposes at 178-179°C. Used as a topical anti-infective.

Upstream & downstream products

Upstream raw materials

Hydroxide

Downstream products

5,7-Dichloro-8-hydroxyquinoline
Additional notes · 1 item

DefinitionChEBI: A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has al o been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.